Table 3.

Table intralymphatic immunotherapy.

Author/Year	Disease	Allergen	Intervention	Age (years)	Number of Patients	Outcome
Hylander et al. 2016106	Allergic Rhinitis	Birch or grass pollen	Double Blind Randomized Placebo Control	20–54	21 (8 females) (15 controls)	Overall met the primary endpoint of symptom reduction by VAS.
Senti et al. 2008104	Allergic Rhinitis	Grass pollen	ILT vs. SCIT	32 ± 8.7 years	58 ILT (20 females)54 SCIT	ILT was safe, effective, induced tolerance faster and tolerance was durable
Senti et al. 2012103	Allergic Rhinitis	Cat (MAT-Fel d 1)	Randomized Placebo controlled	34.6 ± 11.9	12 (8 Females) 8 Placebo	Met the primary end point of increased nasal tolerance
Lee et al. 2015104	Allergic Rhinitis	Dust mite cat, dog	Dust mite, cat and dog ILT	Not reported	10	ILT can rapidly improve rhinitis symptoms, however severe systemic reactions (2) and severe local reaction (1) occurred.